| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082010 | Drug Discovery Today: Disease Mechanisms | 2006 | 7 Pages |
Abstract
The active form of Vitamin D, 1α,25-DihydroxyVitamin D3 [1,25-(OH)2D3] or VitD3 is a potent inhibitor of Th1-mediated immunity. Its capacity to inhibit Th2-mediated immune responses is not yet established with reports of both inhibition and enhancement of Th2 responses. Recent studies from in vitro culture, animal models and limited human clinical studies are reviewed in an attempt to reconcile these data and understand the therapeutic potential of VitD3 in allergic airway disease.
Section editors:Maria Belvisi – Imperial College School of Medicine, London, UKStuart Farrow – GlaxoSmithKline, Stevenage, UK
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Zoë Urry, Nabila Mahfiche, Patricia Ozegbe, Sandra Boswell, Emmanuel Xystrakis, Catherine M Hawrylowicz,